Revenue Breakdown
Composition ()
No data
Revenue Streams
Baxter International Inc (BAX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Infusion Therapies and Technologies, accounting for 36.4% of total sales, equivalent to $1.02B. Other significant revenue streams include Care and Connectivity Solutions and Injectables and Anesthesia. Understanding this composition is critical for investors evaluating how BAX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Baxter International Inc maintains a gross margin of 34.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.66%, while the net margin is -1.80%. These profitability ratios, combined with a Return on Equity (ROE) of -4.70%, provide a clear picture of how effectively BAX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BAX competes directly with industry leaders such as SNN and QGEN. With a market capitalization of $9.98B, it holds a significant position in the sector. When comparing efficiency, BAX's gross margin of 34.39% stands against SNN's 70.62% and QGEN's 62.51%. Such benchmarking helps identify whether Baxter International Inc is trading at a premium or discount relative to its financial performance.
